Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
November 10, 2015
[Management and clinical outcome in patients over 80 years with rectal cancer treated between 2006 and 2008 in Southern France (PACA region)]
L Moureau-Zabotto, J Gal, M Resbeut, et al.
Bulletin Du Cancer
|
May 14, 2009
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study
P Afchain, B Chibaudel, G Lledo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
T André, C Tournigand, L Mineur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial
F C Bidard, F Huguet, C Louvet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2012
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
F Bonnetain, J F Bosset, J P Gerard, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
July 13, 2024
'Folfirinox' chemotherapy combined with contact x-ray brachytherapy 50kVp and 'CAP50' chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study
D Mitrea, N Barbet, T Pacé-Loscos, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Genetic and transcriptomic analyses of early-onset colon cancer (EOCC): a <i>post hoc</i> analysis of 2973 patients from two adjuvant randomized trials
A Gandini, C Gallois, H Blons, et al.
British Journal of Cancer
|
October 14, 2010
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
T Conroy, Y Yataghène, P L Etienne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2008
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
B Chauffert, F Mornex, F Bonnetain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 26, 2009
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study
B Chibaudel, C Tournigand, P Artru, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
November 10, 2015
[Management and clinical outcome in patients over 80 years with rectal cancer treated between 2006 and 2008 in Southern France (PACA region)]
L Moureau-Zabotto, J Gal, M Resbeut, et al.
Bulletin Du Cancer
|
May 14, 2009
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study
P Afchain, B Chibaudel, G Lledo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
T André, C Tournigand, L Mineur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial
F C Bidard, F Huguet, C Louvet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2012
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
F Bonnetain, J F Bosset, J P Gerard, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
July 13, 2024
'Folfirinox' chemotherapy combined with contact x-ray brachytherapy 50kVp and 'CAP50' chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study
D Mitrea, N Barbet, T Pacé-Loscos, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Genetic and transcriptomic analyses of early-onset colon cancer (EOCC): a <i>post hoc</i> analysis of 2973 patients from two adjuvant randomized trials
A Gandini, C Gallois, H Blons, et al.
British Journal of Cancer
|
October 14, 2010
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
T Conroy, Y Yataghène, P L Etienne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2008
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
B Chauffert, F Mornex, F Bonnetain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 26, 2009
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study
B Chibaudel, C Tournigand, P Artru, et al.
Page
of 4